Oral Wegovy: the facts behind the UK's first weight-loss tablet

The misconception: oral semaglutide is a weaker fallback for injection-averse patients

This is the framing that spreads fastest on forums, and it gets things meaningfully wrong. The Wegovy tablet is not a diluted or provisional option. It is a distinct MHRA-authorised medicine, approved following its own phase-3 clinical programme, carrying the same semaglutide molecule as the injection and the same weight-management licence. The difference lies in how the medicine reaches your bloodstream, not in its therapeutic ambition.

Oral semaglutide (wegovy oral form) uses an absorption enhancer called SNAC, which allows a small proportion of the dose to pass through the stomach lining intact. Because oral bioavailability is lower than subcutaneous injection, the tablet's maintenance dose is 25 mg (much higher in absolute terms than the 2.4 mg injection dose) which is how the two formulations arrive at a comparable effect. Understanding that the OASIS 4 trial recorded an average weight reduction of around 13.6% over 64 weeks (and around 16.6% among participants who remained fully adherent throughout) makes it harder to dismiss the tablet as the lesser sibling. You can read more about the clinical evidence and the full licensed pathway on our oral Wegovy for weight loss page.

What the injection still holds in clinical trial comparisons is a modestly higher average figure at the 2.4 mg dose. The honest answer is that the right formulation depends on the person, not on a league table, and that is precisely the kind of decision a prescriber should make with you.

How taking oral Wegovy actually works day to day

The tablet's absorption requirements are stricter than the injection's, and getting them right matters. The MHRA-approved instructions are: take the tablet first thing in the morning, on a completely empty stomach, with a small amount of plain water (up to around 120 ml). Then wait a minimum of 30 minutes before eating, drinking anything else (including coffee or tea), or taking any other oral medicine. Swallowing the tablet whole is essential.

That 30-minute window is where real-world adherence lives. A practical checking habit that takes under a minute: the night before, put the tablet pack somewhere you will see it before you reach the kettle, a specific shelf, a bedside table, next to your phone. The physical cue matters because the most common reason people miss the absorption window is not forgetting to take the tablet, it is reaching for a drink first by reflex.

One significant upside over the injection is storage. The tablet needs no refrigeration, which removes the usual planning involved in travel, hotel stays, or a fridge that runs warm. If you are weighing the two formats, our page on Wegovy oral tablets covers storage, the escalation schedule, and how the tablet compares to the pen in more detail. The dose schedule itself (1.5 mg, then 4 mg, then 9 mg, then 25 mg, at least a month at each step) is decided and guided by your prescriber, not something to adjust independently.

Who the tablet is licensed for, and what the NHS situation looks like

The MHRA licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes, used alongside a reduced-calorie diet and increased physical activity. For some ethnic backgrounds, UK guidance applies slightly lower BMI thresholds; a prescriber factors this in during the clinical assessment. Being within the BMI range is necessary but not sufficient on its own, the prescriber reviews the full picture.

As things stand, Wegovy tablets are not available on the NHS. A NICE appraisal would need to take place before NHS commissioning could begin, and that process has not yet concluded. Private prescription is the route available now. Because this is a prescription-only medicine, the starting point is always a consultation, you can explore what that involves on our treatment page, which covers both Wegovy formats and the injectable alternatives. For a broader look at how oral semaglutide sits within the UK's weight-management landscape, the oral semaglutide page gives the regulatory context alongside the MHRA's published guidance.

The tablet is not suitable during pregnancy, breastfeeding, or when trying to conceive. It is not licensed for anyone under 18. A history of pancreatitis, certain thyroid conditions, or other contraindications makes an honest prescriber conversation essential before starting. The MHRA has published guidance on GLP-1 medicines for weight management, the Yellow Card scheme is also the right place to report any suspected side effects once treatment is under way.

Side effects: what to expect, and what to watch for

The OASIS 4 trial found that gastrointestinal side effects affected around 74% of participants taking oral semaglutide, compared with around 42% in the placebo group. Nausea, diarrhoea, constipation, indigestion, and burping were the most common. The pattern mirrors what the injection produces: most noticeable in the early weeks of treatment or after a dose increase, and in many cases settling down as the body adjusts.

Mild GI symptoms at the start are expected and usually not a reason to stop. What does warrant urgent medical attention is severe, persistent stomach pain that spreads to the back, with or without vomiting, this can be a sign of pancreatitis, a serious but uncommon side effect that the MHRA highlighted in a Drug Safety Update in January 2026. Gallbladder symptoms, signs of significant dehydration, or any allergic reaction also need prompt assessment rather than a wait-and-see approach.

The NHS medicines information for semaglutide (available at NHS: semaglutide) covers the full side-effect profile at a level that is accurate and easy to follow. Reading it before you start, rather than only when something feels off, is time well spent. Our prescribers are also available for aftercare questions seven days a week if something comes up once treatment is under way. If you would like to understand the cost context before booking, our Wegovy oral tablet page sets out what private pricing typically involves, and if you are specifically curious about how the Wegovy pill format is dispensed and what to expect when it arrives, that page walks through the practicalities in full. Patients who want to compare formulations side by side will also find our guide to semaglutide tablets useful, as it covers how the different oral options relate to one another within the licensed range.